A 62-Year-Old Man with Myelofibrosis : Episode 5
Safety Considerations with JAK Inhibitors in Myelofibrosis
Focusing on the safety profiles of JAK2 inhibitors, a myelofibrosis specialist discusses the adverse events encountered with pacritinib, ruxolitinib, and momelotinib.
Video Player is loading.
Case: A 62-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 62-year-old man presented with symptoms of fatigue, night sweats, and increased bruising.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension
- 1 year prior, patient had a “normal” physical and blood work.
- PCP noticed lower Hg (11 to 9.5 g/dL) and Plt (350 to 195 cells/m3)
- Patient was referred to Hem/Onc – first available appoint in 2 months.
Initial Clinical Workup and Diagnosis (Post-PCP Visit):
- Exam: fatigue and night sweats worsening; bone pain.
- Labs: RBC 3.40 x 1012/L; Hb 8.7 g/dL; Hct 36%; MCV 94fL; WBC 28.0 x 109/L; Plt 75 x 109/; LDH 330 IU/L
- Spleen: 5 cm below LCM
- Bone Marrow Fibrosis: Grade 2
- Bone Marrow Blasts: 3%
- Blood Smear: leukoerythroblastosis; 1% blasts by manual count/flow cytometry
- Molecular Analysis: JAK V617F+
- ECOG PS 2
- Diagnosis: Primary MF
Current Treatments:
- Patient was initiated on pacritinib.
Recent Videos
Treatment Implementation and Long-Term Considerations in BPDCN
Academic Perspectives on the Evolving Treatment Landscape in MPNs
Adverse Events Monitoring and Management in BPDCN Treatment
Academic Perspectives on Treatment Decisions for BPDCN
Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
Advances in MPN Management: Insights From MANIFEST-2 and Beyond
Ongoing studies of Ra-223–based combinations
Academic Perspectives on Systemic Therapy for Advanced uHCC
Ongoing studies of Ra- 223–based combinations
Protecting bone health for patients receiving Ra-223 + ARPI combination
Related Content
